Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P Rettig, Reyka G Jayasinghe, Feng Gao, Jeremy Eisele, Leah Gehrs, Julie K. Ritchey, Jaebok Choi, Camille N Abboud, Iskra Pusic, Meagan A Jacoby, Peter Westervelt, Matthew Christopher, Amanda F. Cashen, Armin Ghobadi, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio

Blood blood.2024026497.

https://doi.org/10.1182/blood.2024026497

Published: 2024

Includes: Supplemental data

Journal Articles

Long Non-Coding RNA LINC00XPRR Is Upregulated in Newly Diagnosed Multiple Myeloma Promoting Poor Response to High-Dose Melphalan with Autologous Stem Cell Transplantation and Three-Drug Regimen

Richa Mishra, Katelyn Bagwill, Savannah Gonzales, Vanessa Brizuela, Prasanth Thunuguntla, Yoon Jae Chang, Reyka G. Jayasinghe, Julie Fortier, Mark A. Schroeder, Li Ding, Ravi Vij, John DiPersio, Jessica Silva-Fisher

Blood (2023) 142 (Supplement 1): 4668.

https://doi.org/10.1182/blood-2023-180011

Published: 2023

Journal Articles

One Year Follow-up on the First Patient Treated with Nula-Cel: An Autologous CRISPR/Cas9 Gene Corrected CD34+ Cell Product to Treat Sickle Cell Disease

Blood (2023) 142 (Supplement 1): 5000.

https://doi.org/10.1182/blood-2023-188963

Published: 2023

Journal Articles

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 4707.

https://doi.org/10.1182/blood-2023-186241

Published: 2023

Journal Articles

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Ramzi Abboud, Mark A. Schroeder, Michael P. Rettig, Feng Gao, Julie K. Ritchey, Camille N. Abboud, Iskra Pusic, Peter Westervelt, Amanda F Cashen, Matt Christopher, Armin Ghobadi, Ramzi Abboud, Keith Stockerl-Goldstein, Geoffrey L Uy, John F. DiPersio, Leah Gehrs

Blood (2023) 142 (Supplement 1): 651.

https://doi.org/10.1182/blood-2023-180289

Published: 2023

Journal Articles

Use of Combination Premedication Prior to Motixafortide Administration Reduced Severity and Frequency of AEs in the Phase 3 Genesis Trial - a Single Center Analysis

Zachary David Crees, Keith Stockerl-Goldstein, Mark A. Schroeder, Ravi Vij, Ella Sorani, Irit Gliko Kabir, Inbal Goldstein, Tzipi Lustig, Shaul Kadosh, John F. DiPersio

Blood (2023) 142 (Supplement 1): 3522.

https://doi.org/10.1182/blood-2023-181452

Published: 2023

Journal Articles

Measurable Residual Disease Status By Clonotypic Mass Spectrometry with Easym Assay Predicts Outcomes Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Michael Slade, Abir Khaled, Mark Fiala, Zac McDonald, Mariya Liyasova, Julie Fortier, Mark Zaydman, Sarah Kelley, Zachary David Crees, Mark A. Schroeder, Keith Stockerl-Goldstein, Liqiang Yang, Ravi Vij

Blood (2023) 142 (Supplement 1): 3354.

https://doi.org/10.1182/blood-2023-172440

Published: 2023

Journal Articles

Maintenance Ruxolitinib Is Associated with Low Rates of Chronic Gvhd Requiring Systemic Treatment in Older Adults with AML/MDS Undergoing Allogeneic HCT: Results of a Phase II Multicenter Trial

Zachariah Defilipp, Haesook T. Kim, Laura Knight, Suzanne O'Connor, Meghan White, Bhagirathbhai Dholaria, Mark A. Schroeder, Sumithira Vasu, Sameem Abedin, Areej El-Jawahri, Steven McAfee, Yi-Bin Chen, Gabriela S. Hobbs

Blood (2023) 142 (Supplement 1): 653.

https://doi.org/10.1182/blood-2023-180423

Published: 2023

Journal Articles

Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Meaghan Ryan, Zachary David Crees, Michael Slade, Mark A. Schroeder, Ravi Vij, Geoffrey L Uy, Keith Stockerl-Goldstein

Blood (2023) 142 (Supplement 1): 2217.

https://doi.org/10.1182/blood-2023-179604

Published: 2023

Journal Articles

Updated Findings of a Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Stem Cell Transplantation for Patients with Primary or Secondary Myelofibrosis

Gabriela S. Hobbs, Haesook T. Kim, Suzanne O'Connor, Mark A. Schroeder, Roni Tamari, Sarah A Wall, Areej El-Jawahri, Steven McAfee, Jessica Hem, Patricia Lozano, Jonas S. Jutzi, Ann Mullally, Yi-Bin Chen, Zachariah Defilipp

Blood (2023) 142 (Supplement 1): 2103.

https://doi.org/10.1182/blood-2023-178645

Published: 2023

Journal Articles

Targeting a deubiquitinase blocks GVHD

Mark A. Schroeder

Blood (2023) 141 (12): 1376–1377.

https://doi.org/10.1182/blood.2022019367

Published: 2023

Journal Articles

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Blood (2022) 140 (Supplement 1): 1875–1876.

https://doi.org/10.1182/blood-2022-157214

Published: 2022

Journal Articles

Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)

James E. Hoffman, Brea Lipe, Jason Melear, Michaela Liedtke, Mark A. Schroeder, Ruben Niesvizky, Christopher Strouse, Christopher A. Yasenchak, Damian J. Green, Jeremy Sauer, Yinghui Wang, Phoenix Ho, Al-Ola Abdallah

Blood (2022) 140 (Supplement 1): 10160–10162.

https://doi.org/10.1182/blood-2022-157347

Published: 2022

Journal Articles

Clonotypic Mass Spectrometry with Easym Assay for Detection of Measurable Residual Disease in Multiple Myeloma

Michael J Slade, Abir Khalid, Mark A Fiala, Mariya Liyasova, Mark A Zaydman, Zac McDonald, Julie M Fortier, Sarah Kelley, Zachary D. Crees, Mark A. Schroeder, Keith E Stockerl-Goldstein, Liqiang Yang, Ravi Vij

Blood (2022) 140 (Supplement 1): 4376–4377.

https://doi.org/10.1182/blood-2022-155582

Published: 2022

Journal Articles

Despite Use of Upfront Plerixafor and G-CSF, Daratumumab Exposure Reduces Stem Cell Mobilization in Patients with Multiple Myeloma

Jacob Edmisson, Mark A Fiala, Michael J Slade, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Jingyu Xiang, Zachary D. Crees, Mark A. Schroeder, Keith E Stockerl-Goldstein, John F. DiPersio, Ravi Vij

Blood (2022) 140 (Supplement 1): 4295–4296.

https://doi.org/10.1182/blood-2022-169367

Published: 2022

Journal Articles

Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone

Alexa J Loncharich, Mark A Fiala, Michael J Slade, Angela Vickroy, Margaret Kavanaugh, Kari Wilson, Mark A. Schroeder, Keith E Stockerl-Goldstein, Ravi Vij, Kristen M. Sanfilippo

Blood (2022) 140 (Supplement 1): 8550–8551.

https://doi.org/10.1182/blood-2022-166736

Published: 2022

Journal Articles

The Association of Agent Orange Exposure Duration with Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma Progression: A Population-Based Study

Lawrence Liu, Mei Wang, Nikhil Grandhi, Mark A. Schroeder, Theodore S. Thomas, Akhil Kumar, Kristin Vargo, Feng Gao, Kristen M. Sanfilippo, Su-Hsin Chang

Blood (2022) 140 (Supplement 1): 4356–4357.

https://doi.org/10.1182/blood-2022-167305

Published: 2022

Journal Articles

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Blood (2022) 139 (8): 1177–1183.

https://doi.org/10.1182/blood.2021011532

Published: 2022

Includes: Supplemental data

Journal Articles

Meagan A. Jacoby, David A. Sallman, Bart L. Scott, Megan Haney, Fei Wan, John F. DiPersio, Ramzi Abboud, Keith E. Stockerl-Goldstein, Rami S. Komrokji, Mark A. Schroeder, Matthew J. Walter, Peter Westervelt, Geoffrey L. Uy

Blood (2021) 138 (Supplement 1): 540.

https://doi.org/10.1182/blood-2021-151137

Published: 2021

Journal Articles

A Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Celltransplantation for Patients with Primary or Secondary Myelofibrosis

Gabriela Hobbs, Haesook T. Kim, AJ S. Bottoms, Michael T. Byrne, Mark A. Schroeder, Roni Tamari, Sarah A Wall, Zachariah Defilipp, Areej El-Jawahri, Steven McAfee, Yi-Bin Chen

Blood (2021) 138 (Supplement 1): 169.

https://doi.org/10.1182/blood-2021-146330

Published: 2021

NARROW

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation

Long Non-Coding RNA LINC00XPRR Is Upregulated in Newly Diagnosed Multiple Myeloma Promoting Poor Response to High-Dose Melphalan with Autologous Stem Cell Transplantation and Three-Drug Regimen

One Year Follow-up on the First Patient Treated with Nula-Cel: An Autologous CRISPR/Cas9 Gene Corrected CD34+ Cell Product to Treat Sickle Cell Disease

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

Use of Combination Premedication Prior to Motixafortide Administration Reduced Severity and Frequency of AEs in the Phase 3 Genesis Trial - a Single Center Analysis

Measurable Residual Disease Status By Clonotypic Mass Spectrometry with Easym Assay Predicts Outcomes Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Maintenance Ruxolitinib Is Associated with Low Rates of Chronic Gvhd Requiring Systemic Treatment in Older Adults with AML/MDS Undergoing Allogeneic HCT: Results of a Phase II Multicenter Trial

Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Updated Findings of a Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Stem Cell Transplantation for Patients with Primary or Secondary Myelofibrosis

Targeting a deubiquitinase blocks GVHD

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)

Clonotypic Mass Spectrometry with Easym Assay for Detection of Measurable Residual Disease in Multiple Myeloma

Despite Use of Upfront Plerixafor and G-CSF, Daratumumab Exposure Reduces Stem Cell Mobilization in Patients with Multiple Myeloma

Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone

The Association of Agent Orange Exposure Duration with Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma Progression: A Population-Based Study

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

A Pilot Study of CPX-351 (Vyxeos © ) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome

A Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Celltransplantation for Patients with Primary or Secondary Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only